VIDEO: Trispecific antibody has multiple targets in refractory diabetic macular edema

ByCharles Semba, MD

ByMoira Mahoney

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Charles Semba, MD, chief medical officer of Eluminex Biosciences, discusses a trispecific antibody for refractory diabetic macular edema.

EB-105 has three major moieties that target VEGF-A, VEGF-B, placental growth factor, angiopoietin-2 and interleukin-6 receptor.

“We hope the combination of these three [moieties] will present an incremental breakthrough to really address the difficult nature in treating residual fluid in patients with diabetic eye disease,” Semba said.

Published by:

Sources/Disclosures

Collapse

Source:

Semba C. EB-105: When three is not a crowd – A novel trispecific antibody for retinal disease. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Semba reports being the chief medical officer of Eluminex Biosciences.

Clinical Trials at the Summit meeting

Read more

VIDEO: Trispecific antibody has multiple targets in refractory diabetic macular edema

Related Content